The FDA cracked down on 17 companies illegally selling more than 58 products — mainly dietary supplements — that claimed to prevent, treat, or cure Alzheimer’s disease and other conditions.
A plasma protein classifier may be able to predict amyloid burden in preclinical Alzheimer’s disease. (Science Advances)
Senator Bernie Sanders called out Catalyst Pharmaceuticals for its $375,000/year price tag on Firdapse, the recently approved Lambert-Eaton Myasthenic Syndrome (LEMS) treatment. (NBC News)
Why aren’t more doctors treating addiction with methadone and buprenorphine? (Philadelphia Inquirer)
Federal prosecutors in Philadelphia filed suit to stop the country’s first planned supervised opioid injection site from opening. (NPR)
Hypertension was linked to increased Parkinson’s disease risk, a meta-analysis showed. (Neuroepidemiology)
Blood levels of neurofilament light chain were associated with measures of multiple sclerosis disease activity and neuroaxonal damage and may be a biomarker for the disease. (Neurology)
Neutrophils stuck to the inside of brain capillaries reduced cortical blood flow and impaired memory in mouse models of Alzheimer’s disease. (Nature Neuroscience)
Matthew Bellina, an amyotrophic lateral sclerosis (ALS) patient whose name is on the Right to Try act, says his treatment appears to be working. (Bloomberg)
The first digital diagnostic and therapeutic devices to support earlier autism identification and treatment received FDA breakthrough designations, device maker Cognoa announced.